MYGN Quote, Financials, Valuation and Earnings

Enovis Corp. has a net margin of -3.77% compared to Myriad Genetics, Inc.'s net margin of -90.11%. Myriad Genetics, Inc.'s return on equity of -72.17% beat Enovis Corp.'s return on equity of -52.38%.

Myriad Genetics, Inc. has a consensus price target of $7.78, signalling upside risk potential of 63.79%. On the other hand Enovis Corp. has an analysts' consensus of $45.18 which suggests that it could grow by 99.57%. Given that Enovis Corp. has higher upside potential than Myriad Genetics, Inc., analysts believe Enovis Corp. is more attractive than Myriad Genetics, Inc..

Myriad Genetics, Inc. has a beta of 1.865, which suggesting that the stock is 86.45% more volatile than S&P 500. In comparison Enovis Corp. has a beta of 1.245, suggesting its more volatile than the S&P 500 by 24.467%.

Myriad Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myriad Genetics, Inc. pays -- of its earnings as a dividend. Enovis Corp. pays out -- of its earnings as a dividend.

Myriad Genetics, Inc. quarterly revenues are $209.8M, which are smaller than Enovis Corp. quarterly revenues of $575.8M. Myriad Genetics, Inc.'s net income of -$7.9M is higher than Enovis Corp.'s net income of -$518.8M. Notably, Myriad Genetics, Inc.'s price-to-earnings ratio is -- while Enovis Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics, Inc. is 0.55x versus 0.57x for Enovis Corp.. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Holdings, Inc. has a net margin of -3.77% compared to Myriad Genetics, Inc.'s net margin of 2.67%. Myriad Genetics, Inc.'s return on equity of -72.17% beat iRhythm Holdings, Inc.'s return on equity of -40.07%.

Myriad Genetics, Inc. has a consensus price target of $7.78, signalling upside risk potential of 63.79%. On the other hand iRhythm Holdings, Inc. has an analysts' consensus of $211.43 which suggests that it could grow by 81.02%. Given that iRhythm Holdings, Inc. has higher upside potential than Myriad Genetics, Inc., analysts believe iRhythm Holdings, Inc. is more attractive than Myriad Genetics, Inc..

Myriad Genetics, Inc. has a beta of 1.865, which suggesting that the stock is 86.45% more volatile than S&P 500. In comparison iRhythm Holdings, Inc. has a beta of 1.180, suggesting its more volatile than the S&P 500 by 17.985%.

Myriad Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myriad Genetics, Inc. pays -- of its earnings as a dividend. iRhythm Holdings, Inc. pays out -- of its earnings as a dividend.

Myriad Genetics, Inc. quarterly revenues are $209.8M, which are larger than iRhythm Holdings, Inc. quarterly revenues of $208.9M. Myriad Genetics, Inc.'s net income of -$7.9M is lower than iRhythm Holdings, Inc.'s net income of $5.6M. Notably, Myriad Genetics, Inc.'s price-to-earnings ratio is -- while iRhythm Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics, Inc. is 0.55x versus 4.99x for iRhythm Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pacific Biosciences of California, Inc. has a net margin of -3.77% compared to Myriad Genetics, Inc.'s net margin of -90.43%. Myriad Genetics, Inc.'s return on equity of -72.17% beat Pacific Biosciences of California, Inc.'s return on equity of -389.62%.

Myriad Genetics, Inc. has a consensus price target of $7.78, signalling upside risk potential of 63.79%. On the other hand Pacific Biosciences of California, Inc. has an analysts' consensus of $2.58 which suggests that it could grow by 92.79%. Given that Pacific Biosciences of California, Inc. has higher upside potential than Myriad Genetics, Inc., analysts believe Pacific Biosciences of California, Inc. is more attractive than Myriad Genetics, Inc..

Myriad Genetics, Inc. has a beta of 1.865, which suggesting that the stock is 86.45% more volatile than S&P 500. In comparison Pacific Biosciences of California, Inc. has a beta of 2.332, suggesting its more volatile than the S&P 500 by 133.164%.

Myriad Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacific Biosciences of California, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myriad Genetics, Inc. pays -- of its earnings as a dividend. Pacific Biosciences of California, Inc. pays out -- of its earnings as a dividend.

Myriad Genetics, Inc. quarterly revenues are $209.8M, which are larger than Pacific Biosciences of California, Inc. quarterly revenues of $44.6M. Myriad Genetics, Inc.'s net income of -$7.9M is higher than Pacific Biosciences of California, Inc.'s net income of -$40.4M. Notably, Myriad Genetics, Inc.'s price-to-earnings ratio is -- while Pacific Biosciences of California, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics, Inc. is 0.55x versus 2.51x for Pacific Biosciences of California, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care, Inc. has a net margin of -3.77% compared to Myriad Genetics, Inc.'s net margin of -0.2%. Myriad Genetics, Inc.'s return on equity of -72.17% beat Tandem Diabetes Care, Inc.'s return on equity of -121.88%.

Myriad Genetics, Inc. has a consensus price target of $7.78, signalling upside risk potential of 63.79%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $30.76 which suggests that it could grow by 65.3%. Given that Tandem Diabetes Care, Inc. has higher upside potential than Myriad Genetics, Inc., analysts believe Tandem Diabetes Care, Inc. is more attractive than Myriad Genetics, Inc..

Myriad Genetics, Inc. has a beta of 1.865, which suggesting that the stock is 86.45% more volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.737, suggesting its more volatile than the S&P 500 by 73.689%.

Myriad Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myriad Genetics, Inc. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.

Myriad Genetics, Inc. quarterly revenues are $209.8M, which are smaller than Tandem Diabetes Care, Inc. quarterly revenues of $290.4M. Myriad Genetics, Inc.'s net income of -$7.9M is lower than Tandem Diabetes Care, Inc.'s net income of -$589K. Notably, Myriad Genetics, Inc.'s price-to-earnings ratio is -- while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics, Inc. is 0.55x versus 1.22x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.